(Q46671524)

24 December 2017

title

Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer (English)

1 reference

24 December 2017

main subject

osteoporosis

0 references

author name string

Laura Boehnke Michaud

series ordinal

1

1 reference

24 December 2017

publication date

1 April 2010

1 reference

24 December 2017

American Journal of Health-System Pharmacy

published in

1 reference

24 December 2017

volume

67

1 reference

24 December 2017

issue

7 Suppl 3

1 reference

24 December 2017

page(s)

S20-30; quiz S31-3

1 reference

24 December 2017

Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

The thyroid and breast cancer: a significant association?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

The thyroid, iodine and breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Natural history of progression after PSA elevation following radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

NCCN Task Force Report: Bone Health in Cancer Care

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Practical guidance for the management of aromatase inhibitor-associated bone loss

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Changes in Bone Mineral Density After Adjuvant Aromatase Inhibitors and Fracture Risk in Breast Cancer Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Risk-benefit profiles of raloxifene for women

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Future treatment of bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100078

31 March 2020

Identifiers

DOI

10.2146/AJHP100078

1 reference

24 December 2017

1 reference

24 December 2017